Testing of compounds for inhibition of CYP enzymes
Ended Purchase Order Awarded Last action
- Contract number
- 75N95020P00597
- Awardee
-
Cyprotex US LLC UEI YNGLSAF57T14
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $81,900
Award facts
- Opportunity
-
- Testing of compounds for inhibition of CYP enzymes Solicitation · 75N95020Q00305 · Posted Sep 1, 2020
- Contract value 100% obligated
- $81,900.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Watertown, MA 02472, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$5,970 | |
| Other Administrative Action | $0 | |
| Original award | $87,870 |
About this award
The National Institute on Drug Abuse awarded a $81.9K firm fixed-price purchase order to Cyprotex US LLC on September 10, 2020, for testing of compounds to inhibit cytochrome P450 (CYP) enzymes. The contract, with an ultimate completion date of June 21, 2022, was executed with fiscal year 2020 funding that required administrative de-obligation in preparation for the September 30, 2025, closing of the period of availability for those funds. The work was performed at Cyprotex's facility in East Watertown, Massachusetts. No small business set-aside was utilized for this procurement, reflecting Cyprotex's competitive position based on specialized scientific capabilities.
Cyprotex US LLC is a foreign-owned contract research organization headquartered in Framingham, Massachusetts, specializing in predictive toxicology and in vitro testing services including cytochrome P450 inhibition assays and absorption, distribution, metabolism, and excretion (ADME) screening. The company maintains an established relationship with multiple federal agencies including the Environmental Protection Agency, National Institutes of Health, National Cancer Institute, and National Center for Advancing Translational Sciences. Cyprotex holds a significant $13M Indefinite Delivery Indefinite Quantity contract with the EPA's Office of Research and Development to support the High Throughput Toxicokinetics program, under which the company has received multiple delivery orders totaling over $3.5M. The NIDA purchase order represents part of Cyprotex's broader portfolio of specialized compound testing services supporting federal research objectives in chemical risk assessment and drug development.
Quick answers
Who was awarded contract 75N95020P00597?
75N95020P00597 was awarded to Cyprotex US LLC by National Institute on Drug Abuse (National Institutes of Health) on September 10, 2020.
How much is contract 75N95020P00597 worth?
The government has obligated $81,900 on 75N95020P00597.
Was contract 75N95020P00597 competed?
The extent of competition for 75N95020P00597 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award